Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Tee

Cardiovascular Disease Hyattsville, MD Medical Doctor

NPI 1811980584 CMS profile 36966

3415 Hamilton St, Ste 1, Hyattsville, MD 20782

Open in the dashboard

General payments

$8,746

277 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Tee of Hyattsville, MD is reported in the CMS Open Payments database as having received $8,746 across 277 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $50 1
2020 General $1,004 38
2019 General $7,692 238

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Tee
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Steven Tee were reported at $50. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Steven Tee Cardiovascular Disease median Middle half National median
2019 $7,692 $450 $127–$1,392 $163
2020 $1,004 $242 $77–$751 $114
2021 $0 $335 $101–$1,037 $132
2022 $0 $395 $121–$1,211 $149
2023 $0 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $50 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,357 38 payments
  2. Novo Nordisk Inc $1,098 37 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $666 20 payments
  4. Sanofi-Aventis U.S. LLC $648 18 payments
  5. Abbott Laboratories $552 4 payments
  6. Pfizer Inc. $476 15 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $362 11 payments
  8. Lilly USA, LLC $331 11 payments
  9. Gilead Sciences, Inc. $320 14 payments
  10. Amgen Inc. $293 8 payments
  11. Other $2,643 101 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,605 266 payments
  2. Education $96 10 payments
  3. Grant $45 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $888 20 payments
  2. JARDIANCE Diabetes $666 20 payments
  3. Tresiba $368 16 payments
  4. Ozempic $352 14 payments
  5. Xultophy 100/3.6 $349 14 payments
  6. JARDIANCE Diabetes $323 10 payments
  7. CardioMEMS HF System $296 2 payments
  8. Repatha $293 8 payments
  9. XARELTO $279 8 payments
  10. ELIQUIS $268 8 payments
  11. Other $5,765 237 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

277 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record